Immunome Stock News & Updates

[WKN: A2QD9D | Symbol: IMNM]
Immunome

Immunome (IMNM) in the Pivotal Point Check: Phase 3 Success with Varegacestat in Desmoid Tumors - Significant Improvement in Progression-Free Survival and 56% Response Rate Pave the Way for FDA Approval 2026!

Immunome Inc. (IMNM): CEO Uses Capital Increase for a Private Investment of $1.16 Million

Immunome Inc. (IMNM) specializes in the development of targeted therapies to improve treatment outcomes...

  • ‹
  • 1
  • ›